|
|
 |
| TAG closely monitors HIV antiretroviral drugs in all stages of development, including post-marketing. We advocate for the expeditious development, proper clinical research and regulation, ease of access and optimal use of these drugs. We work with other treatment activists and researchers, FDA, NIH, and the pharmaceutical industry to achieve these objectives. TAG also helps educate members of the HIV community about antiretrovirals. |
[ home ] [ what's new ] [ current reports ] [ 2003 ] [ resource links ] [ archived reports ] |
|
what's new
|
|
current reports
- 2008 Pipeline Report
Press Release
HIV, Tuberculoses, Hepatitis B, Hepatitis C: drugs, diagnostics, vaccines and microbicides in development.
- The 2007 Pipeline Report

Experimental Treatments and Preventive Therapies for HIV, Hepatitis C, and Tuberculosis July 2007
- Who's got the POWER? TAG position paper on darunavir/r approval

examining data and drug interactions on TMC114/r brand name Prezista®, a ritonavir (r) -boosted protease inhibitor
- AIDS Activism, Boehringer Ingelheim, and the Broken Social Contract

Remarks by Mark Harrington at BI Symposium "HIV: From Yesterday to Tomorrow"
- CROI Report 2006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO
- Antiretrovirals in the Pipeline July 05
chapter from full report, also in separate pdf format
- Lactic acidosis
a side-effect of the long term use of the reverse transcriptase inhibitor (RTI) class of HIV drugs (added 9/19/2005)
- TAG supports approval of Aptivus™ brand tipranavir
- Position paper on accelerated FDA approval for novel protease inhibitor tipranavir
- Zero Tolerance (added 3/16/2005)
2005 Pipeline Reportpart I Complications
- Epzicom brand abacavir/lamivudine QD: the difference between drugs and new drugs
- Two out of three ain't bad: Truvada enters the market at full blast
- PEPFAR and expedited antiretroviral review
HHS announced an expedited FDA review process for antiretroviral fixed dose combination (FDC) products
- NIH: Open the Doors
NIH Hearing on Norvir 400% price increase
- Breaking barriers or breaking the bank?

Position paper on Fuzeon brand enfuvirtide (T-20)
- CROI 2004 Pipeline Report
- WHO Guidelines for Antiretroviral Therapy

Scaling up antiretroviral therapy in resource limited-settings 2003 Revision
- Position paper on 908 (fosamprenavir)
- Position paper on FTC (emtricitabine) brand name Emtriva approval
- ICAAC Roundup (posted 3/14/2005)
Report from the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the annual meeting of the American Society for Microbiology.
2003
- Retrovirus 2003 Conference Antivirals Pipeline Report
- References
- Position Paper on Atazanavir (BMS-232623), brand name Reyataz®
- Report from the 3rd International STI Workshop
Montréal, Quebec, Canada - March 23-24 2002. Sponsored by: Foundation for AIDS & Immune Research, The Forum for Collaborative HIV Research, Gay Men's Health Crisis, Project Inform, Treatment Action Group
- Coming, Going and Gone: The Drug Development Pipeline, 2002
- Ten Texts on Saquinavir: Its Rapid Rise & Fall

A saga of drug the development process. Current and earlier texts about saquinavir (Invirase), activists against, pharmaceutical and FDA for.
- STI 2000
(pdf format only)
Structured Treatment Interruptions Workshop October 13-15, 2000 Newton, MA. Summary of current and proposed research protocols.
- Therapeutic Drug Monitoring (TDM): Ready for Prime Time? by Mark Harrington
- Survey of Structured Treatment Interruptions Reports
- Structured Treatment Interruptions Workshop Report
Resource Links
2003 WHO ART Guidelines
Scaling Up Antiretroviral Therapy in Resource Limited Settings: Treatment Guidelines for a Public Health Approach 2003 Revision
Archived Reports
- New HIV Treatment Guidelines Could Revolutionize HIV Care for People with AIDS (6/19/97)
- Saquinavir Scam (6/11/97)
- Current Treatment Strategies: 14 Points to Consider (2/25/97)
- NIH Panel to Define Principles of Therapy of HIV Infection, Department of the Interior Auditorium, 13-14 November 1996. zipped Word version | zipped text version
- Problems with Protease Inhibitor Development Plans
- Written for the National Task Force on AIDS Drug Development, February 23, 1995, Washington, D.C. Discusses development and research of protease inhibitors with recommendations for future clinical trial design. zipped Word-formatted version for downloading | zipped text version for downloading
- The Challenge Ahead by Gregg Gonzalves
- 36 basic scientists working in AIDS interviewed during April and May 1993 discuss scientific issues, practical problems, and outline practical means of remedying the situation. zipped Word version for downloading
- The Crisis in AIDS Research by Mark Harrington
- An overview of AIDS research, written in 1993, with suggestions for changes in fundamental approaches to how the virus, treatments, and research goals are viewed. zipped Word version for downloading
- AIDS Research at the NIH: A Critical Review by Gregg Gonsalves and Mark Harrington
- Part I: Summary. Part II: The NIH, A User's Guide. VIII International Conference on AIDS, Amsterdam, the Netherlands, July 20, 1992. zipped Word versions for downloading: Part I | Part II

|
Each of these papers is available in hard copy format by writing or calling TAG at the address and numbers below. Please note that all papers provided here are dated. While the information contained in them is important, treatment options have changed since the dates of their writing.
TAG papers are provided here in zipped text-only format for downloading and reading with a text editor. If you don't have an unzip application, you can download shareware called pkunzip for DOS, WinZip for Windows, or Zipit for Macs. Extract the zipped program onto your harddrive and associate the zip extension with the application both in your browser and on your harddrive. Then when you click on a zipped file to download, your harddrive will automatically unzip the file and you'll be able to read it with whatever text reader or word processing application you use.
|
TAG index 
|